Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.27 -0.02 (-0.08%)
Streaming Delayed Price Updated: 10:02 AM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Stock Pick ↗
Catalyst Pharmaceuticals (CPRX) exemplifies the GARP strategy with strong growth, high profitability, and a reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Bullish Technical Setup ↗
Catalyst Pharmaceuticals (CPRX) combines strong growth fundamentals with a bullish technical setup, offering a rare biotech investment opportunity. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes the Caviar Cruise Quality Investing Screen ↗
Catalyst Pharmaceuticals exemplifies quality investing with high growth, exceptional profitability, a debt-free balance sheet, and an attractive valuation. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Represents an Affordable Growth Opportunity ↗
Catalyst Pharmaceuticals offers strong growth, solid profitability, and a debt-free balance sheet, all at an attractive valuation compared to its biotech peers. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗
Discover Catalyst Pharmaceuticals (CPRX), a growth stock with strong earnings and a bullish technical breakout pattern, signaling potential upside. 
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment on Caviar Cruise Screen ↗
Catalyst Pharmaceuticals is a high-quality growth stock with exceptional profitability, zero debt, and strong cash flow, making it a standout in the biotech sector. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential ↗
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong EPS growth, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong growth, solid earnings, and an affordable valuation for investors seeking value. 
Via Chartmill
News headline image
What Does the Market Think About Catalyst Pharmaceuticals Inc? ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals ↗
Catalyst Pharmaceuticals (CPRX) appears undervalued with strong financials: zero debt, high profitability, and robust growth, making it a compelling value investing candidate. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗
Discover Catalyst Pharmaceuticals (CPRX): a high-growth biotech stock with strong profitability, a solid balance sheet, and an attractive valuation. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals ↗
Catalyst Pharmaceuticals (CPRX) is a value investing candidate with strong fundamentals, low P/E ratios, robust financial health, high profitability, and impressive growth in the rare disease sector. 
Via Chartmill
News headline image
How Is The Market Feeling About Catalyst Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation ↗
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate ↗
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech ↗
Catalyst Pharmaceuticals (CPRX) is a strong value stock with low P/E ratios, high profitability, zero debt, and impressive growth, offering a solid margin of safety. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals ↗
Catalyst Pharmaceuticals (CPRX) offers strong growth, fair valuation, and solid financials, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales ↗
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria,... 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential ↗
Combine technical & fundamental analysis to spot growth stocks like Catalyst Pharmaceuticals (CPRX), showcasing strong financials & breakout potential. 
Via Chartmill
News headline image
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential ↗
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender in Affordable Growth Stocks ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth stocks. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors ↗
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors. 
Via Chartmill
News headline image
Peering Into Catalyst Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential ↗
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks. 
Via Chartmill
News headline image
Is Catalyst Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.